BIOSYENT INC (RX.CA) Stock Fundamental Analysis
Canada - TSX-V:RX - CA0906901081 - Common Stock
11.82 CAD
0 (0%)
We assign a fundamental rating of 8 out of 10 to RX. RX was compared to 35 industry peers in the Pharmaceuticals industry. RX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. RX is not valued too expensively and it also shows a decent growth rate. These ratings could make RX a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
RX had positive earnings in the past year.
In the past year RX had a positive cash flow from operations.
In the past 5 years RX has always been profitable.
RX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of RX (18.29%) is better than 100.00% of its industry peers.
The Return On Equity of RX (21.72%) is better than 100.00% of its industry peers.
The Return On Invested Capital of RX (20.16%) is better than 97.14% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for RX is significantly above the industry average of 7.75%.
The last Return On Invested Capital (20.16%) for RX is above the 3 year average (16.58%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.29% | ||
| ROE | 21.72% | ||
| ROIC | 20.16% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
1.3 Margins
RX has a better Profit Margin (20.43%) than 97.14% of its industry peers.
RX's Profit Margin has been stable in the last couple of years.
RX has a better Operating Margin (25.92%) than 97.14% of its industry peers.
RX's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 78.51%, RX belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
RX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.92% | ||
| PM (TTM) | 20.43% | ||
| GM | 78.51% |
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RX is creating value.
Compared to 1 year ago, RX has less shares outstanding
Compared to 5 years ago, RX has less shares outstanding
RX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 15.32 indicates that RX is not in any danger for bankruptcy at the moment.
RX's Altman-Z score of 15.32 is amongst the best of the industry. RX outperforms 97.14% of its industry peers.
RX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
The Debt to FCF ratio of RX (0.14) is better than 97.14% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that RX is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.02, RX is doing good in the industry, outperforming 74.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 15.32 |
ROIC/WACC2.16
WACC9.34%
2.3 Liquidity
A Current Ratio of 4.90 indicates that RX has no problem at all paying its short term obligations.
The Current ratio of RX (4.90) is better than 97.14% of its industry peers.
RX has a Quick Ratio of 4.00. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
RX has a Quick ratio of 4.00. This is amongst the best in the industry. RX outperforms 97.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4 |
3. Growth
3.1 Past
RX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.16%, which is quite good.
Measured over the past years, RX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.02% on average per year.
RX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.55%.
Measured over the past years, RX shows a quite strong growth in Revenue. The Revenue has been growing by 10.33% on average per year.
EPS 1Y (TTM)14.16%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%35.23%
Revenue 1Y (TTM)16.55%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%41.96%
3.2 Future
Based on estimates for the next years, RX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.98% on average per year.
The Revenue is expected to grow by 10.14% on average over the next years. This is quite good.
EPS Next Y22.6%
EPS Next 2Y18.57%
EPS Next 3Y14.98%
EPS Next 5YN/A
Revenue Next Year17.51%
Revenue Next 2Y12.24%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RX is valuated rather expensively with a Price/Earnings ratio of 19.06.
Compared to the rest of the industry, the Price/Earnings ratio of RX indicates a rather cheap valuation: RX is cheaper than 85.71% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of RX to the average of the S&P500 Index (27.30), we can say RX is valued slightly cheaper.
The Price/Forward Earnings ratio is 13.47, which indicates a correct valuation of RX.
Based on the Price/Forward Earnings ratio, RX is valued cheaply inside the industry as 82.86% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, RX is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.06 | ||
| Fwd PE | 13.47 |
4.2 Price Multiples
77.14% of the companies in the same industry are more expensive than RX, based on the Enterprise Value to EBITDA ratio.
RX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. RX is cheaper than 77.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.58 | ||
| EV/EBITDA | 10.4 |
4.3 Compensation for Growth
RX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RX's earnings are expected to grow with 14.98% in the coming years.
PEG (NY)0.84
PEG (5Y)1.27
EPS Next 2Y18.57%
EPS Next 3Y14.98%
5. Dividend
5.1 Amount
RX has a Yearly Dividend Yield of 1.65%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 3.60, RX pays a better dividend. On top of this RX pays more dividend than 94.29% of the companies listed in the same industry.
RX's Dividend Yield is slightly below the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.65% |
5.2 History
RX has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
RX pays out 27.09% of its income as dividend. This is a sustainable payout ratio.
DP27.09%
EPS Next 2Y18.57%
EPS Next 3Y14.98%
TSX-V:RX (9/12/2025, 7:00:00 PM)
11.82
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners17.89%
Ins Owner ChangeN/A
Market Cap135.69M
Analysts82.86
Price Target13.26 (12.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.65% |
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP27.09%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.41%
EPS NY rev (3m)-7.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.72%
Revenue NY rev (3m)0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.06 | ||
| Fwd PE | 13.47 | ||
| P/S | 3.55 | ||
| P/FCF | 19.58 | ||
| P/OCF | 19.41 | ||
| P/B | 3.77 | ||
| P/tB | 4.37 | ||
| EV/EBITDA | 10.4 |
EPS(TTM)0.62
EY5.25%
EPS(NY)0.88
Fwd EY7.42%
FCF(TTM)0.6
FCFY5.11%
OCF(TTM)0.61
OCFY5.15%
SpS3.33
BVpS3.14
TBVpS2.7
PEG (NY)0.84
PEG (5Y)1.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.29% | ||
| ROE | 21.72% | ||
| ROCE | 26.88% | ||
| ROIC | 20.16% | ||
| ROICexc | 38.14% | ||
| ROICexgc | 51.16% | ||
| OM | 25.92% | ||
| PM (TTM) | 20.43% | ||
| GM | 78.51% | ||
| FCFM | 18.11% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexcg growth 3Y-33.84%
ROICexcg growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 8.61% | ||
| Cap/Sales | 0.15% | ||
| Interest Coverage | 175 | ||
| Cash Conversion | 65.89% | ||
| Profit Quality | 88.61% | ||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4 | ||
| Altman-Z | 15.32 |
F-Score6
WACC9.34%
ROIC/WACC2.16
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)14.16%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%35.23%
EPS Next Y22.6%
EPS Next 2Y18.57%
EPS Next 3Y14.98%
EPS Next 5YN/A
Revenue 1Y (TTM)16.55%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%41.96%
Revenue Next Year17.51%
Revenue Next 2Y12.24%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
EBIT growth 1Y21.41%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year41.79%
EBIT Next 3Y15.52%
EBIT Next 5YN/A
FCF growth 1Y76.2%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y76.53%
OCF growth 3Y22.83%
OCF growth 5Y14.5%